Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07543926

New Treatment of Common Wart

this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Common Warts (Verruca Vulgaris) DNA Virus Infections Infections Papillomavirus Infections Skin Diseases Skin Diseases, Infectious Skin Diseases, Viral Skin and Connective Tissue Diseases Tumor Virus Infections Virus Diseases Warts

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sohag University

Sohag, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Age more than or equal to 18 years
  • Clinically and dermoscopically confirmed Common warts of both sex
  • patient not receiving previous treatment at least one month before recruitment in our study
  • Single or multiple lesions suitable for injection.

Exclusion criteria

  • Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .

Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .

Treatment and study plan

PRF group

Biological

intralesional PRF injection in common warts

Vitamin D

Drug

intralesional vitamin D injection in common wart

Primary outcomes

  1. treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )

    Time frame: 1 session every 2 weeks for 3 months

    treatment of common wart by intralesional injection of PRF

  2. changes in common warts after treatment by PRF (measuring complete clearance and recurrence of the lesions ,asking about patient satisfaction )

    Time frame: 6 months after the last session

Study contacts

Contact information is provided by the study sponsor or research team.

basma alaaeldin mohamed, resident

CONTACT

[email protected]

01093827856

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 22, 2026
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.